Skip to content
Oncology Research Hub

Salt Lake City, Utah

Cancer clinical trials in Salt Lake City, UT

174 cancer studies are recruiting participants at sites in Salt Lake City as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Salt Lake City at a glance

  • 174 studies are recruiting at a site in Salt Lake City.
  • By phase: Early Phase 1 (2), Phase 1 (25), Phase 1/2 (31), Phase 2 (36), Phase 2/3 (5), Phase 3 (48), No phase (16), Observational (11). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (84), industry (77), government (13).
  • By research area: Lymphoma (60), Breast Cancer (42), Lung Cancer (29), Melanoma (16), Prostate Cancer (15), Pancreatic Cancer (12).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Salt Lake City

Basic details from each study's public record (the 30 most recently updated of 174). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Huntsman Cancer Institute University of Utah
    Registry record
    NCT07488676 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Utah, Huntsman Cancer Institute ( Site 0056)
    Registry record
    NCT06841354 · updated
  3. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 19 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Intermountain Health
    Registry record
    NCT06586957 · updated
  4. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT06982521 · updated
  5. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT05633654 · updated
  6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Huntsman Cancer Institute/University of Utah · University of Utah Sugarhouse Health Center
    Registry record
    NCT05879926 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Lung cancer studies recruiting in Salt Lake City

  1. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT07063745 · updated
  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    University of Utah
    Registry record
    NCT07659782 · updated
  3. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT04665739 · updated
  4. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT07458347 · updated
  5. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Huntsman Cancer Institute ( Site 0042)
    Registry record
    NCT06312137 · updated
  6. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT07020221 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Prostate cancer studies recruiting in Salt Lake City

  1. TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT07190300 · updated
  2. Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    University of Utah
    Study site
    Huntsman Cancer Institute at University of Utah
    Registry record
    NCT07216248 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Melanoma studies recruiting in Salt Lake City

  1. Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Utah
    Study site
    Huntsman Cancer Institute at University of Utah
    Registry record
    NCT04844528 · updated
  2. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT05136196 · updated
  3. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University of Utah Huntsman Cancer Institute
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Lymphoma studies recruiting in Salt Lake City

  1. A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

    • No phase
    • Ages 1 to 25
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT05621291 · updated
  2. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT06724237 · updated
  3. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    University of Utah
    Registry record
    NCT07221500 · updated
  4. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Primary Children's Hospital
    Registry record
    NCT06173518 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Primary Children's Hospital
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Huntsman Cancer Institute/University of Utah · Primary Children's Hospital
    Registry record
    NCT05675410 · updated
  8. TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    • Phase 1/2
    • Up to age 1
    • All sexes
    Sponsor
    Tanja Andrea Gruber
    Study site
    University of Utah Huntsman Cancer Institute
    Registry record
    NCT05848687 · updated
  9. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Huntsman Cancer Institute - Oncology Division
    Registry record
    NCT06091254 · updated
  10. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT06337318 · updated
  11. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Huntsman Cancer Institute at The University of Utah
    Registry record
    NCT05091424 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Salt Lake City

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US053
    Registry record
    NCT07522073 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Huntsman Cancer Institute/University of Utah · University of Utah Sugarhouse Health Center
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Ask about studies near Salt Lake City

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call